Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
Recruiting
Observational Study
Myelofibrosis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 55 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 650 (estimated)
- Sponsor
- Center for International Blood and Marrow Transplant Research · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMT…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients fulfilling the following criteria will be eligible for inclusion in the study:
* PMF, post-ET MF, or post-PV MF.
* Int-2 or high-risk disease as determined by the DIPSS.
* Age ≥55 at the time of DIPSS assessment.
* For the alloHCT arm:
* Donors must be a…
Contacts